Shandong Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG, and what generic alternatives to SHANDONG drugs are available?
SHANDONG has nine approved drugs.
There are five US patents protecting SHANDONG drugs. There is one tentative approval on SHANDONG drugs.
There are twenty-seven patent family members on SHANDONG drugs in fourteen countries and eleven supplementary protection certificates in eight countries.
Drugs and US Patents for Shandong
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-004 | Jan 13, 2023 | RX | Yes | Yes | 9,446,135 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-003 | Jan 13, 2023 | RX | Yes | Yes | 11,110,094 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-004 | Jan 13, 2023 | RX | Yes | Yes | 10,098,882 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-002 | Jan 13, 2023 | RX | Yes | Yes | 9,446,135 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-003 | Jan 13, 2023 | RX | Yes | Yes | 10,098,882 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Shandong | SEVOFLURANE | sevoflurane | LIQUID;INHALATION | 214382-001 | Aug 18, 2023 | AN | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-002 | Jan 13, 2023 | RX | Yes | Yes | 11,110,094 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shandong Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 6072121 | ⤷ Try a Trial |
Hungary | E052864 | ⤷ Try a Trial |
Japan | 2015143259 | ⤷ Try a Trial |
Spain | 2607497 | ⤷ Try a Trial |
Hong Kong | 1185560 | ⤷ Try a Trial |
China | 103338752 | ⤷ Try a Trial |
Spain | 2749864 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shandong Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0521471 | C300125 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106 |
0720599 | CR 2014 00048 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724 |
0720599 | C300688 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724 |
0521471 | SPC/GB03/033 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321 |
0521471 | 0391023-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: ROSUVASTATIN |
0521471 | 03C0043 | France | ⤷ Try a Trial | PRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106 |
0720599 | 92544 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.